Could a simple supplement help memory? new safety study launches
NCT ID NCT07583251
First seen May 17, 2026 · Last updated May 17, 2026
Summary
This early-stage study will test whether a dietary supplement called gamma glutamylcysteine (GGC) is safe for people with mild cognitive impairment (MCI), a condition that can lead to memory loss. Nine volunteers aged 55 to 80 will take different doses of GGC daily for three months. Researchers will monitor kidney and liver function and any side effects to see if larger studies are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD COGNITIVE IMPAIRMENT(MCI) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Presbyterian Hospital
Pittsburgh, Pennsylvania, 15213, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.